fidanacogene elaparvovec Beqvez hemophilia B
Selected indexed studies
- Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B. (N Engl J Med, 2024) [PMID:39321362]
- Fidanacogene Elaparvovec for Hemophilia B - A Multiyear Follow-up Study. (N Engl J Med, 2025) [PMID:40239068]
- ** (, 2024) [PMID:39088666]
_Worker-drafted node — pending editorial review._
Connections
fidanacogene elaparvovec Beqvez hemophilia B is a side effect of
Sources
- Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B. (2024) pubmed
- Fidanacogene Elaparvovec for Hemophilia B - A Multiyear Follow-up Study. (2025) pubmed
- PMID:39088666 (2024) pubmed
- PMID:38648311 (2024) pubmed
- Fidanacogene Elaparvovec: First Approval. (2024) pubmed
- Gene-based therapies for hemophilia. (2025) pubmed
- Health-related quality of life in adults with hemophilia B after gene therapy with fidanacogene elaparvovec: results from the BENEGENE-2 trial. (2026) pubmed
- Gene therapy for hemophilia - From basic science to first approvals of "one-and-done" therapies. (2025) pubmed
- Population Modeling of Factor IX Activity Following Administration of Fidanacogene Elaparvovec Gene Therapy in Participants with Hemophilia B. (2025) pubmed
- Beqvez - another gene therapy for hemophilia B. (2024) pubmed